Author of

• 25520

  +

  Poster Display session (Friday) (ID 65)

  • Event: ELCC 2018
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1

  • 25264

    +

    34P - Recommendations for EGFR mutation testing with a fast and fully automated sample-to-result system: How to optimize DNA input instead of using lung cancer tissue? (Now Available) (ID 563)

    12:30 - 12:30  |  Presenting Author(s): C. Chapusot
    • Abstract
    • Slides

    Background:
    EGFR mutation detection on non-small cell lung carcinoma (NSCLC) is mandatory for optimal care of metastatic patients. Rearrangement/amplification of ALK or ROS, PDL1 expression level, BRAF, HER2 mutational status is also required. These different tests are time and tissue consuming. Therefore, molecular diagnostic laboratories need to elaborate strategies in order to optimize the realization of these different tests from limited biopsy specimens. The Idylla™ EGFR Mutation Test provided by Biocartis® is a fully automated sample–to–result test based on real-time PCR. The test allows the detection of 51 EGFR mutations directly from slices of FFPE tissue samples in less than three hours with an overall agreement of 96% with pyrosequencing. Nevertheless, further molecular tests need DNA and further tissue processing. In this project, the feasibility of EGFR testing from extracted DNA of NSCLC samples using Idylla™ EGFR was evaluated.
    
    Methods:
    EGFR mutational status was evaluated with the Idylla™ EGFR cartridge in two independent series of 20 retrospective and 83 prospective cases using DNA samples extracted from NSCLC instead of tissue sections.
    
    Results:
    Tumoral cellularity, DNA quantity and quality evaluated with a Tapestation Agilent® were taken into account in addition to the WT DNA CQ value calculated by the Idylla™ Explore software to optimize the DNA input. EGFR mutational status of the 20 retrospective cases previously analyzed with pyrosequencing was assessed in order to check the agreement of the fully automated method. A prospective series of 83 samples was then analyzed. All the results were interpreted and validated with the use of the Idylla™ test specific software, and qPCR curves were visualized by the Idylla™ Explore software.
    
    Conclusions:
    These results suggest some recommendations to use already extracted DNA with a fully automated sample–to–result system taking into account preanalytics and analytics features to safely characterize EGFR mutational status on lung cancer samples.
    
    Clinical trial identification:
    
    
    Legal entity responsible for the study:
    University Hospital of Dijon
    
    Funding:
    Biocartis company
    
    Disclosure:
    All authors have declared no conflicts of interest.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.